Published in
Cambridge University Press, Infection Control and Hospital Epidemiology, p. 1-4, 2021
DOI: 10.1017/ice.2021.452
Links
Tools
Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE)
Journal article published in 2021 by
Katie J. Suda,
Alfredo Traversa,
Ursula Patel,
Linda Poggensee,
Margaret A. Fitzpatrick 
,
Geneva M. Wilson,
Charlesnika T. Evans
,
Geneva M. Wilson,
Charlesnika T. Evans
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract We assessed trends in treatment of patients with CRE from 2012 through 2018. We detected decreased utilization of aminoglycosides and colistin and increased utilization in extended-spectrum cephalosporins and ceftazidime-avibactam. We found significant uptake of ceftazidime-avibactam, a newly approved antibiotic, to treat CRE infections.